Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy

References

• WadeSWStraderCFitzpatrickLAAnthonyMSO’MalleyCDEstimating prevalence of osteoporosis: examples from industrialized countriesArch Osteoporos2014918224847682
   PubMed Web of Science ®Google Scholar
• ChenPLiZHuYPrevalence of osteoporosis in China: a meta-analysis and systematic reviewBMC Public Health2016161103927716144
   PubMed Web of Science ®Google Scholar
• CompstonJESkeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structureBone20074061447145217045858
   PubMed Web of Science ®Google Scholar
• GallagherJCGenantHKCransGGVargasSJKregeJHTeriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fracturesJ Clin Endocrinol Metab20059031583158715613428
   PubMed Web of Science ®Google Scholar
• OrwollESScheeleWHPaulSThe effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosisJ Bone Miner Res200318191712510800
   PubMed Web of Science ®Google Scholar
• GreenspanSLBoneHGEttingerMPEffect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trialAnn Intern Med2007146532633917339618
   PubMed Web of Science ®Google Scholar
• VestergaardPJorgensenNRMosekildeLSchwarzPEffects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk – a meta-analysisOsteoporos Int2007181455716951908
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorESirisESWehrenLEOsteoporosis and fracture risk in women of different ethnic groupsJ Bone Miner Res200520218519415647811
   PubMed Web of Science ®Google Scholar
• NaitoCEthnic factors in the acceptability of foreign clinical dataTher Innov Regul Sci19983211283S1292S
   Google Scholar
• UyamaYShibataTNagaiNHanaokaHToyoshimaSMoriKSuccessful bridging strategy based on ICH E5 guideline for drugs approved in JapanClin Pharmacol Ther200578210211316084844
   PubMed Web of Science ®Google Scholar
• DaiKChenDZhangZComparison of the effects of subcutaneous teriparatide and intranasal calcitonin in treating established osteoporosis in postmenopausal Chinese womenChin J Osteoporos Bone Miner Res201142331
   Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar
• LiuYYeKMathurAKHuiSFuerstTPGenantHKComparative calibration without a gold standardStat Med19971616188919059280040
   PubMed Web of Science ®Google Scholar
• AustinPCAn introduction to propensity score methods for reducing the effects of confounding in observational studiesMultivariate Behav Res201146339942421818162
   PubMed Web of Science ®Google Scholar
• PrevrhalSKregeJHChenPGenantHBlackDMTeriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessmentCurr Med Res Opin200925492192819250060
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellODe LaetCJonssonBOdenAOgelsbyAKInternational variations in hip fracture probabilities: implications for risk assessmentJ Bone Miner Res20021771237124412096837
   PubMed Web of Science ®Google Scholar
• CauleyJADefining ethnic and racial differences in osteoporosis and fragility fracturesClin Orthop Relat Res201146971891189921431462
   PubMed Web of Science ®Google Scholar
• YasudaSUZhangLHuangSMThe role of ethnicity in variability in response to drugs: focus on clinical pharmacology studiesClin Pharmacol Ther200884341742318615002
   PubMed Web of Science ®Google Scholar
• International HapMapCThe international HapMap projectNature2003426696878979614685227
   PubMed Web of Science ®Google Scholar
• WilsonJFWealeMESmithACPopulation genetic structure of variable drug responseNat Genet200129326526911685208
   PubMed Web of Science ®Google Scholar
• Obermayer-PietschBMMarinFMcCloskeyEVEffects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatmentJ Bone Miner Res200823101591160018505369
   PubMed Web of Science ®Google Scholar
• TsujimotoMUenakaKIwataAHigashiuchiYSowaHEffects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacyJ Bone Miner Metab201230332633721938381
   PubMed Web of Science ®Google Scholar
• ChenJFYangKHZhangZLA systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in AsiaOsteoporos Int2015261112825138261
   PubMed Web of Science ®Google Scholar
• Forteo [package insert]Indianapolis INEli Lilly and Company2016
   Google Scholar
• ChesnutCH3rdSilvermanSAndrianoKA randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study GroupAm J Med2000109426727610996576
   PubMed Web of Science ®Google Scholar
• ChuNNLiXNChenWLXuHRPharmacokinetics and safety of recombinant human parathyroid hormone (1–34) (teriparatide) after single ascending doses in Chinese healthy volunteersPharmazie2007621186987118065105
   PubMed Web of Science ®Google Scholar
• SatterwhiteJHeathmanMMillerPDMarinFGlassEVDobnigHPharmacokinetics of teriparatide (rhPTH[1–34]) and calcium pharmacodynamics in postmenopausal women with osteoporosisCalcif Tissue Int201087648549220953593
   PubMed Web of Science ®Google Scholar
• YiSAnHLeeHKorean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessmentPharmacogenet Genom20142410477485
   Web of Science ®Google Scholar
• HwangJSTuSTYangTSChenJFWangCJTsaiKSTeriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosisOsteoporos Int200617337337816421647
   PubMed Web of Science ®Google Scholar